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1

BACKGROUND. Insulin is a key regulator of metabolic function. The effects of excess adiposity, insulin resistance, and hepatic
steatosis on the complex integration of insulin secretion and hepatic and extrahepatic tissue extraction are not clear.
METHODS. A hyperinsulinemic-euglycemic clamp and a 3-hour oral glucose tolerance test were performed to evaluate insulin
sensitivity and insulin kinetics after glucose ingestion in 3 groups: (a) lean subjects with normal intrahepatic triglyceride
(IHTG) and glucose tolerance (lean-NL; n = 14), (b) obese subjects with normal IHTG and glucose tolerance (obese-NL; n = 24),
and (c) obese subjects with nonalcoholic fatty liver disease (NAFLD) and prediabetes (obese-NAFLD; n = 22).
RESULTS. Insulin sensitivity progressively decreased and insulin secretion progressively increased from the lean-NL to the
obese-NL to the obese-NAFLD groups. Fractional hepatic insulin extraction progressively decreased from the lean-NL to
the obese-NL to the obese-NAFLD groups, whereas total hepatic insulin extraction (molar amount removed) was greater in
the obese-NL and obese-NAFLD subjects than in the lean-NL subjects. Insulin appearance in the systemic circulation and
extrahepatic insulin extraction progressively increased from the lean-NL to the obese-NL to the obese-NAFLD groups. Total
hepatic insulin extraction plateaued at high rates of insulin delivery, whereas the relationship between systemic insulin
appearance and total extrahepatic extraction was linear.
CONCLUSION. Hyperinsulinemia after glucose ingestion in obese-NL and obese-NAFLD is due to an increase in insulin
secretion, without a decrease in total hepatic or extrahepatic insulin extraction. However, the liver’s maximum capacity
to remove insulin is limited because of a saturable extraction process. The increase in insulin delivery to the liver and
extrahepatic tissues in obese-NAFLD is unable to compensate for the increase in insulin resistance, resulting in impaired
glucose homeostasis.
TRIAL REGISTRATION. ClinicalTrials.gov NCT02706262.
FUNDING. NIH grants DK56341 (Nutrition Obesity Research Center), DK052574 (Digestive Disease Research Center), RR024992
(Clinical and Translational Science Award), and T32 DK007120 (a T32 Ruth L. Kirschstein National Research Service Award); the
American Diabetes Foundation (1-18-ICTS-119); Janssen Research & Development; and the Pershing Square Foundation.

Introduction

Obesity is associated with nonalcoholic fatty liver disease (NAFLD),
multiorgan insulin resistance, and hyperinsulinemia, which are
major risk factors for both type 2 diabetes and coronary heart disease
(1–4). Although hyperinsulinemia and insulin resistance are likely
involved in the pathogenesis of NAFLD (5), excess intrahepatic triglyceride (IHTG) content could also contribute to hyperinsulinemia
and insulin resistance. The liver is important in regulating systemic
plasma insulin concentrations, because it is the major site for insulin
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clearance; in individuals who are lean and healthy, a large portion
(~50%) of the insulin delivered to the liver is cleared during firstpass transit, and an additional 20% is cleared through subsequent
passes (6, 7). The remaining 30% of insulin secreted by the pancreas
is removed by extrahepatic organs, primarily the kidneys and skeletal muscle (6, 8). Increased insulin secretion and impaired hepatic insulin clearance in individuals with NAFLD could contribute to
insulin resistance by chronic exposure of insulin-sensitive tissues to
large amounts of insulin, which can downregulate insulin receptor
binding affinity and insulin receptor numbers (9–12). Even 24 hours
of an experimentally induced increase in plasma insulin concentration causes hepatic and skeletal muscle insulin resistance (13), and a
single dose of a pharmacological agent that decreases insulin secretion lowers 24-hour plasma glucose and insulin concentrations and
improves oral glucose tolerance (14) in healthy, lean adults. However, the relationship between IHTG content and insulin kinetics is not
clear because of conflicting data from different studies that found
jci.org   Volume 130   Number 6   June 2020
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plasma glucose concentrations, plasma
glucose 2 hours after glucose ingestion,
and hemoglobin A1c (HbA1c) were
Lean-NL (n = 14)
Obese-NL (n = 24) Obese-NAFLD (n = 22)
higher in the obese-NAFLD group
Body weight, kg
65 ± 2
106 ± 4A
116 ± 4A
than in the obese-NL and lean-NL
2
A
A
BMI, kg/m
23 ± 1
38 ± 1
40 ± 1
A
A
groups, with no differences between
FFM, kg
46 ± 2
55 ± 2
59 ± 2
A
A
the obese-NL and lean-NL groups
Body fat, %
28 ± 2
47 ± 1
48 ± 1
(Table 1). Fasting plasma insulin and
IHTG content, %
1.6 ± 0.1
2.4 ± 0.2
21.0 ± 1.4A,B
C-peptide concentrations increased
HbA1c, %
5.0 ± 0.1
5.1 ± 0.1
5.7 ± 0.1A,B
Fasting glucose, mmol/L
4.7 ± 0.1
4.9 ± 0.1
5.6 ± 0.1A,B
progressively from the lean-NL to the
Fasting insulin, pmol/L
36 ± 3
84 ± 7A
196 ± 23A,B
obese-NL to the obese-NAFLD groups
Fasting C-peptide, pmol/L
487 ± 34
826 ± 34A
1,491 ± 94A,B
(Table 1). Both hepatic insulin sensiOGTT 2-hour glucose, mmol/L
5.3 ± 0.3
6.0 ± 0.2
9.4 ± 0.3A,B
tivity (assessed as the reciprocal of the
HISI, 100/(μmol/kg FFM/min × μU/mL)
1.13 ± 0.12
0.53 ± 0.04A
0.30 ± 0.03A,B
product of basal endogenous glucose
Glucose Rd/insulin, (nmol/kg FFM/min)/(pmol/L)
89 ± 6
56 ± 5A
30 ± 2A,B
production rate and basal plasma insuValues represent the mean ± SEM. HISI, hepatic insulin sensitivity index. A 1-way ANOVA with post hoc
lin concentration) and muscle insulin
testing where appropriate was used to identify significant mean differences among groups. AP < 0.05, value
sensitivity (assessed as the glucose dissignificantly different from the corresponding value in the lean-NL group; BP < 0.05, value significantly
posal rate relative to the plasma insudifferent from the corresponding value in the obese-NL group.
lin concentration during the HECP)
decreased progressively from the leanNL to the obese-NL to the obese-NAFLD groups (Table 1).
insulin secretion was either increased or the same and insulin clearPlasma glucose, insulin, and C-peptide responses to glucose ingesance was either decreased or the same in individuals with NAFLD
tion. Both plasma glucose concentrations and plasma glucose AUC
compared with those with normal IHTG content (15–18). The reason
after glucose ingestion were greater in the obese-NAFLD group
for the differences between studies could be related to differences in
than in the obese-NL and lean-NL groups, which were not significharacteristics of the study subjects and the methods used to assess
cantly different from each other (Figure 1, A and B). Plasma insuIHTG content and insulin metabolism.
lin and C-peptide concentrations and AUC after glucose ingestion
The purpose of the present study was to provide a comprehenincreased progressively from the lean-NL to the obese-NL to the
sive evaluation of the complex interrelationship among obesity,
obese-NAFLD groups (Figure 1, C–F). The plasma insulin conceninsulin resistance, hepatic steatosis, and insulin kinetics. A hyperintration AUC in the obese-NAFLD group was 2-fold greater than
sulinemic-euglycemic clamp procedure (HECP), in conjunction with
that in the obese-NL group and 3.5 times greater than in the leanstable isotopically labeled glucose tracer infusion, and a 3-hour oral
NL group, whereas the plasma C-peptide concentration AUC was
glucose tolerance test (OGTT) were used to evaluate insulin sensionly 50% greater in the obese-NAFLD group than in the obese-NL
tivity and insulin kinetics in 3 cohorts of individuals who differed in
group and 2-fold greater than in the lean-NL group.
adiposity, insulin sensitivity, and IHTG content: (a) lean with normal
Insulin kinetics. The kinetics model accurately described the
IHTG content and normal fasting glucose and oral glucose tolerance
insulin data from both the OGTT and HECP (average normal(lean-NL), (b) obese with normal IHTG content and normal fasting
ized root mean square error: 6.3% ± 3.5%) (Supplemental Figure
glucose and oral glucose tolerance (obese-NL), and (c) obese with
1; supplemental material available online with this article; https://
high IHTG content and evidence of abnormal glucose metabolism
doi.org/10.1172/JCI136756DS1). The amount of insulin delivered
(impaired fasting glucose or oral glucose tolerance) (obese-NAFLD).
to the liver comprises both insulin secreted by β cells and insulin
We used a recently developed modeling approach (15, 19) in conthat passes through the liver into the systemic circulation and is
junction with C-peptide deconvolution to assess different aspects of
recycled back to the liver. Both the insulin secretion rate (ISR)
insulin kinetics in response to glucose ingestion, including the insuand the rate of insulin recycled back to the liver during the 3-hour
lin secretion rate and hepatic, extrahepatic, and whole-body insulin
OGTT increased progressively from the lean-NL to the obese-NL
plasma clearance and tissue extraction rates. A better understandto the obese-NAFLD groups (Figure 2A). Fractional hepatic insulin
ing of the interrelationships among adiposity, IHTG content, insuextraction (i.e., the fraction of insulin delivered to the liver that is
lin sensitivity, and insulin kinetics can provide new insights into the
removed by the liver) decreased progressively from the lean-NL to
mechanisms that regulate glucose homeostasis in individuals with
the obese-NL to the obese-NAFLD groups and was significantly
obesity and those with obesity and NAFLD.
lower in the obese-NAFLD group than in the obese-NL and leanNL groups (Figure 2B). However, the rate of total hepatic insulin
extraction (i.e., the molar amount of insulin removed from plasma
Results
by the liver per minute) progressively increased from the lean-NL
Body composition and metabolic characteristics. The obese-NL and
to the obese-NL to the obese-NAFLD groups and was greater in
obese-NAFLD groups were matched with regard to BMI and body fat
both the obese-NAFLD and obese-NL groups than in the lean-NL
percentage, but IHTG content was 9-fold greater in the obese-NAgroup, with no difference observed between the obese-NAFLD and
FLD group than in the obese-NL group, with no difference in IHTG
obese-NL groups (Figure 2C). Although the fractional extraction
content between the lean-NL and obese-NL groups (Table 1). Fasting

Table 1. Body composition and metabolic characteristics of the study subjects
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Figure 1. Plasma glucose, insulin, and C-peptide
responses to glucose ingestion. Plasma glucose,
insulin, and C-peptide concentrations before and over
a 3-hour period after ingesting a 75-g glucose drink
(A, C, and E), and plasma glucose, insulin, and C-peptide 3-hour concentration AUC values (B, D, and F) in
the lean-normal (NL), obese-NL, and obese-NAFLD
groups. White, gray, and black circles in A, C, and E
represent the lean-NL (n = 14), obese-NL (n = 24), and
obese-NAFLD (n = 22) groups, respectively. Values in
B, D, and F represent the mean ± SEM. P values were
determined by 1-way ANOVA with post hoc testing to
identify significant mean differences between groups
when appropriate. *P < 0.05, value significantly
different from the lean-NL value; †P < 0.05, value
significantly different from the obese-NL value.

of insulin by extrahepatic tissues (i.e., the fraction of insulin delivered to extrahepatic tissues that is removed) was not different in
the lean-NL (34% ± 2%), obese-NL (28% ± 3%), or obese-NAFLD
(30% ± 2%) (P = 0.60) group, the rate of total extrahepatic insulin
extraction (i.e., the molar amount of insulin removed by extrahepatic tissues per minute) progressively increased from the lean-NL
to the obese-NL to the obese-NAFLD groups and was more than
double the rate in the obese-NAFLD group than in the obeseNL group (Figure 2D). The rate of total (whole-body) insulin
extraction increased progressively from the lean-NL to the obeseNL to the obese-NAFLD groups because of increases in both total
hepatic and extrahepatic insulin extraction rates (Figure 2E). The
liver accounted for approximately 70% of whole-body insulin
extraction in the lean-NL and obese-NL groups, but only approximately 50% in the obese-NAFLD group; conversely, extrahepatic
insulin extraction increased from approximately 30% of wholebody insulin extraction in the lean-NL and obese-NL groups to
approximately 50% in the obese-NAFLD group (Figure 2F). The
relationship between the rate of insulin delivered to the liver (i.e.,
ISR and posthepatic insulin that is not removed by extrahepatic tissues and is recycled back to the liver) and the rate of total
hepatic insulin extraction demonstrated a saturable process that
began to plateau with the increase in hepatic insulin delivery rates

observed in the obese-NL group, with considerable variability in the rate of hepatic insulin
extraction at any given rate of insulin delivery
(Figure 2G). In contrast, the total extrahepatic
insulin extraction rate increased linearly with
increasing rates of insulin delivery into the systemic circulation (i.e., total posthepatic insulin
appearance in plasma) (Figure 2H).
Interrelationships among insulin sensitivity,
plasma insulin concentration, IHTG content, and
insulin kinetics. The whole-body insulin clearance rate (i.e., volume of plasma cleared of insulin per minute) during the OGTT was positively
correlated with insulin sensitivity (assessed as
the glucose rate of disposal relative to the plasma insulin concentration [glucose Rd/I] during
the HECP) (Figure 3A), whereas the whole-body
insulin extraction rate (i.e., the molar amount of
insulin removed per minute) was negatively correlated with muscle insulin sensitivity (Figure 3B). The rate of whole-body insulin
clearance was negatively correlated with the plasma insulin AUC
during the OGTT (Figure 3C), whereas the whole-body insulin
extraction rate was positively correlated with the plasma insulin
AUC and was best described by a saturable, Michaelis-Menten
relationship (ref. 20 and Figure 3D), presumably driven by the saturability of hepatic insulin extraction. We observed no significant
correlation between either the fractional hepatic insulin extraction
rate or the total hepatic insulin extraction rate and IHTG content
in the obese-NAFLD group (Supplemental Figure 2).
Indices of β cell function. The ISR during the OGTT was inversely
correlated with muscle insulin sensitivity, and the ISR increased as
muscle insulin sensitivity decreased in a curvilinear fashion (Figure
4A). The β cell function index (i.e., the incremental ISR in relation
to muscle insulin sensitivity), which provides a measure of insulin
secretion by β cells in relation to insulin sensitivity, decreased progressively from the lean-NL to the obese-NL to the obese-NAFLD
groups and was significantly lower in the obese-NAFLD group
than in the lean-NL and obese-NL groups (Figure 4B). Therefore,
the high ISR in the obese-NL group adequately compensated for
the decrease in insulin sensitivity needed to maintain normal oral
glucose tolerance. However, even the very high ISR in the obese-
jci.org   Volume 130   Number 6   June 2020
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Figure 2. Insulin kinetics after glucose ingestion. Rate of total insulin delivered to the liver,
comprising the rate of insulin secreted from β
cells (white bars) and the rate of insulin recycled
from the systemic circulation back to the liver
(gray bars) (A), fractional hepatic insulin extraction
(B), rate of total hepatic insulin extraction (C),
rate of total extrahepatic insulin extraction (D),
absolute contribution of hepatic (white bars) and
extrahepatic (gray bars) insulin extraction to the
total rate of whole-body insulin extraction (E), and
relative contribution of hepatic (white bars) and
extrahepatic (gray bars) extraction to the total rate
of whole-body insulin extraction (F) in the lean-NL
(n = 14), obese-NL (n = 23), and obese-NAFLD (n
= 21) groups. Values represent the mean ± SEM
and indicate the averages for 3 hours after glucose
ingestion. A 1-way ANCOVA with race and sex as
covariates and post hoc testing where appropriate
were used to identify significant mean differences
between groups. *P < 0.05, value significantly
different from the lean-NL value; † P < 0.05, value
significantly different from the obese-NL value.
Relationship between insulin delivery to the liver
and the rate of total hepatic insulin extraction
(G) and relationship between the insulin delivery
rate into the systemic circulation and the rate of
total extrahepatic insulin extraction (H) in lean-NL
(white circles; n = 14), obese-NL (gray circles; n =
23), and obese-NAFLD (black circles; n = 21) participants. Logarithmic and linear regression analyses
were performed to determine the line of best fit to
the data in G and H, respectively.

NAFLD group was not adequate to compensate for the further
decrease in insulin sensitivity in the obese-NAFLD group, resulting
in abnormal glucose tolerance (Figure 1A).

Discussion

We conducted an OGTT and a HECP in 3 carefully characterized
cohorts of participants who were either lean with normal glucose
tolerance and normal IHTG content, obese with normal glucose
tolerance and normal IHTG content, or obese with prediabetes and
NAFLD to help dissect the effects of adiposity, insulin resistance,
and hepatic steatosis on insulin kinetics. Based on the assessment
3308
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of hepatic and muscle insulin sensitivity measured during the HECP, these groups represented a progressive deterioration in insulin
sensitivity from the lean-NL to the obeseNL to the obese-NAFLD groups. We used a
recently developed modeling approach (15,
19) and C-peptide deconvolution to provide
a comprehensive analysis of insulin kinetics in response to glucose ingestion, including insulin secretion by β cells and hepatic,
extrahepatic, and whole-body insulin plasma clearance and tissue extraction rates.
The major findings from our study are: (a)
the ISR in response to glucose ingestion progressively increased from the lean-NL to the
obese-NL to the obese-NAFLD groups, but β
cell function, assessed as the increase in ISR in relation to insulin
sensitivity, was lower in the obese-NAFLD group than in the leanNL and obese-NL groups; (b) hepatic steatosis does not impair the
rate of hepatic insulin extraction (molar amount of insulin removed
from plasma per unit of time), and total hepatic insulin extraction
rates were greater in the obese-NL and obese-NAFLD groups
than in the lean-NL group, but were not different between the
obese-NAFLD and obese-NL groups; (c) the rate of total extrahepatic insulin extraction progressively increased from the lean-NL
to the obese-NL to the obese-NAFLD groups; (d) the total hepatic insulin extraction rate plateaued when hepatic insulin delivery

The Journal of Clinical Investigation  
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Figure 3. Relationships among insulin sensitivity
and insulin concentration after glucose ingestion and
whole-body insulin clearance and extraction rates.
Relationships among whole-body insulin clearance
and extraction rates assessed for 3 hours after ingestion of a 75-g glucose drink and muscle insulin sensitivity, calculated as the glucose Rd (in nmol/kg FFM/
min) divided by the plasma insulin (I) concentration
(in pmol/L) during a HECP (A and B), and the plasma
insulin concentration AUC (C and D). White, gray, and
black circles represent participants in the lean-NL (n
= 14), obese-NL (n = 24 in A and C and n = 23 in B and
D), and obese-NAFLD (n = 22 in A and C and n = 21 in
B and D) groups, respectively. Logarithmic regression
analysis was used to determine the lines of best fit to
the data in A–C, with Michaelis-Menten kinetics used
to describe the line of best fit in D.

(from newly secreted and recycled insulin) was high, whereas the
total extrahepatic insulin extraction rate increased linearly with
increasing delivery of insulin into the systemic circulation; and (e)
the whole-body insulin clearance rate (volume of plasma cleared of
insulin) was positively correlated, whereas the whole-body insulin
extraction rate (the molar amount of insulin removed by all tissues)
was negatively correlated with muscle insulin sensitivity. Our data
demonstrate that the greater increase in plasma insulin concentrations in response to an oral glucose challenge in the obese-NL and
obese-NAFLD groups compared with that observed in the lean-NL
group is due to an increase in insulin secretion, not a reduction in
total insulin extraction by the liver or extrahepatic tissues. However, the liver’s capacity to remove insulin is a saturable process
that reaches maximum capacity when hepatic insulin delivery
is high, which occurred after glucose ingestion in our obese-NL
and obese-NAFLD subjects. In contrast, extrahepatic insulin
extraction after glucose ingestion increased linearly with increases
in insulin delivery into the systemic circulation. Nonetheless, the
marked increases in hepatic and extrahepatic insulin delivery and
extraction in the obese-NAFLD group were not adequate to compensate for the decrease in insulin sensitivity, resulting in impaired
glucose homeostasis.
Systemic plasma insulin concentration is determined by the
rate of insulin secretion by β cells and the rate of insulin removal
by the liver and extrahepatic tissues. The results from our study
provide an integrated assessment of insulin kinetics in response
to an oral glucose challenge, including rates of insulin secretion,
hepatic and extrahepatic insulin extraction, and recycling of posthepatic insulin back to the liver in distinct cohorts of individuals
who differed in adiposity, IHTG content, and hepatic and muscle insulin sensitivity (Figure 5). The data demonstrate that both
insulin secreted by the pancreas and insulin recycled from the
systemic circulation progressively increased the total delivery

of insulin to the liver (prehepatic insulin) from
lean-NL to obese-NL to obese-NAFLD groups.
The liver’s ability to increase the rate of insulin
extraction when insulin delivery to the liver was
increased, as in the obese-NL and obese-NAFLD groups, was limited, presumably because
of a saturable hepatic insulin transport system
(21–23). Therefore, an increase in the delivery of insulin to the
liver was associated with a decrease in fractional hepatic insulin
extraction, and more insulin passed through the liver into the systemic circulation. Most of the insulin that entered the systemic
circulation (posthepatic insulin) was recycled back to the liver,
but a progressively increasing amount of insulin was removed by
extrahepatic tissues (primarily the kidneys and skeletal muscle)
(6, 8) in the lean-NL, obese-NL, and obese-NAFLD groups. In all
groups, more than 99% of insulin secreted by β cells was removed
by hepatic and extrahepatic tissues during the 180-minute OGTT.
However, small differences between the rate of insulin secretion
and removal among the 3 groups resulted in marked differences
in plasma insulin concentration at the 180-minute time point (60
± 22, 158 ± 38, and 532 ± 80 pmol/L in the lean-NL, obese-NL,
and obese-NALFD groups, respectively) (Figure 1C). These results
demonstrate that the major factor responsible for hyperinsulinemia in individuals with obesity who have insulin resistance and
NAFLD is β cell hypersecretion in conjunction with a saturable
insulin extraction process in the liver.
Although there was a large range in IHTG content in the
obese-NAFLD group, we found no correlation between either
fractional hepatic insulin extraction or the rate of total hepatic
insulin extraction and the severity of steatosis. In addition, the
total hepatic insulin extraction rate was not significantly different between the obese-NAFLD and obese-NL groups. These
results challenge the notion that NAFLD per se impairs hepatic
insulin extraction. However, we also found considerable variability in the hepatic insulin extraction rate at any given rate of
insulin delivery to the liver in the obese-NL and obese-NAFLD
groups. The reasons for the heterogeneity in the rates of total
hepatic insulin extraction are not clear but could be related to
individual subject variability in some of the assumed values the
kinetic model uses, such as hepatic blood flow and C-peptide
jci.org   Volume 130   Number 6   June 2020
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Figure 4. Indices of β cell function. (A) Relationship between muscle insulin sensitivity, calculated as the glucose Rd (in nmol/kg FFM/min) divided
by the plasma insulin (I) concentration (in pmol/L) during a HECP, and the
mean insulin secretion rate, assessed for 3 hours after ingestion of a 75-g
glucose drink in lean-NL (white circles; n = 14), obese-NL (gray circles; n
= 24), and obese-NAFLD (black circles; n = 22) participants. Logarithmic
regression analysis was used to determine the line of best fit to the data.
(B) β Cell function index, calculated as the product of the incremental
insulin secretion rate (in nmol × min) for 3 hours after glucose ingestion
(ΔISR0–180) and muscle insulin sensitivity. Values represent the mean ±
SEM. A 1-way ANCOVA with race and sex as covariates and post hoc testing where appropriate were used to identify significant mean differences
between groups. *P <0.05, value significantly different from the lean-NL
value; †P <0.05, value significantly different from the obese-NL value.

kinetics, differences in the expression of insulin receptors, and
differences in the content of intrahepatic proteins involved in
insulin degradation, namely hepatic carcinoembryonic antigen–related cell adhesion molecule 1 (CEACAM1) and insulin-degrading enzyme (IDE) (24).
In individuals with normal glucose tolerance, there is a hyperbolic relationship between insulin sensitivity and the increase in
plasma insulin concentration in response to an oral or intravenous
glucose challenge; the product of these 2 variables is known as the
disposition index (DI) (25–27). Accordingly, DI values are maintained when a decrease or increase in insulin sensitivity is compensated by a corresponding increase or decrease, respectively, in
the plasma insulin response to a glucose load (28–30). However,
the prevailing plasma insulin concentration is a function of both
the rate of insulin secretion and the rate of insulin removal. Therefore, the DI concept implies that β cells and the liver are somehow
able to sense changes in whole-body insulin sensitivity and adjust
the rate of insulin secretion and removal as needed to prevent
hypoglycemia, while increasing circulating insulin to compensate
for insulin resistance. The data from our study suggest that insulin
3310
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secretion drives this process, whereas hepatic insulin extraction
is likely a passive function of insulin delivery that becomes saturated at high insulin delivery rates. Despite the very high ISR
and plasma insulin concentrations after glucose ingestion in the
obese-NAFLD group, postprandial plasma glucose concentrations
were much higher in the obese-NAFLD group than in the obeseNL and lean-NL groups. Therefore, the increased β cell response
and increase in plasma insulin concentrations in the obese-NAFLD group were unable to compensate for the increase in insulin
resistance, which is consistent with the observed lower β cell function index (i.e., incremental insulin secretion in relation to insulin
sensitivity) in the obese-NAFLD group than in the lean-NL and
obese-NL groups.
Our study was unable to determine whether the increased
ISRs in the obese-NL and obese-NAFLD groups were a cause or a
consequence of insulin resistance, or possibly both. The increased
ISRs could be due to a proposed β cell compensatory response to
insulin resistance (31), which is consistent with the inverse correlation between the ISR and whole-body insulin sensitivity observed
among subjects in our entire cohort. However, the mechanism
responsible for the ability of the β cell to “sense” insulin resistance
in other tissues has not been identified. Increased insulin secretion can also be caused by intrinsic β cell hyperreactivity to substrate, hormonal and neural stimuli, and even environmental pollutants (32, 33). In addition, the normal feedback suppression of
insulin secretion by circulating insulin is blunted in obese individuals (34). Accordingly, hyperinsulinemia in individuals with obesity could lead to a “vicious insulin cycle,” in which increased insulin secretion causes insulin resistance, which in turn stimulates
increased insulin secretion. The high rate of insulin secretion and
plasma insulin concentrations can have adverse long-term clinical consequences, because a high ISR is a risk factor for developing type 2 diabetes (29, 32). These findings suggest that the most
effective approach for preventing prediabetes and type 2 diabetes
in obese individuals should include interventions that decrease
insulin secretion and plasma concentration (35, 36).
Several limitations of our study should be considered. First,
differences in insulin secretion and clearance rates have been
reported among different racial/ethnic groups (37–39), so the
results from our study, which primarily included White (65%)
and African American (27%) participants, might not apply to other racial/ethnic populations. In an effort to reduce the potential
confounding effect of race, we included race as a covariate in our
statistical analyses. In addition, we performed additional analyses that evaluated the data from the White and African American participants separately. All significant differences between
lean-NL, obese-NL, and obese-NAFLD groups and significant
correlations between outcome measures were maintained when
evaluating White participants only. The same pattern of differences in outcomes between groups and the correlations between outcomes were maintained for the African American participants, but
some of these assessments did not achieve statistical significance
because of inadequate sample size in this subgroup. Second, the
model used to assess insulin kinetics includes estimated values
for C-peptide kinetic parameters and hepatic blood flow that are
based on standard estimates that do not fully account for interindividual variability and are assumed to be the same during the
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Figure 5. Integrated summary of insulin kinetics after glucose ingestion. Values represent the mean rates (in pmol/min) for β cell insulin secretion, tissue insulin extraction, and insulin accumulation in the systemic circulation, assessed for 3 hours after ingestion of a 75-g glucose drink. Insulin secretion
by the pancreas into the portal circulation increased progressively from the lean-NL to the obese-NL to the obese-NAFLD groups. In addition, a large
portion of insulin that entered the portal circulation was not immediately removed by the liver and extrahepatic tissues and was recycled back to the liver
via the portal vein and hepatic artery, so the total amount of insulin delivered to the liver (newly secreted and recycled insulin) also increased progressively
from the lean-NL to the obese-NL to the obese-NAFLD groups. Although the fractional hepatic extraction of delivered insulin progressively decreased, the
rate of total hepatic insulin extraction progressively increased from the lean-NL to the obese-NL to the obese-NAFLD groups. However, the rate of hepatic
insulin extraction plateaued when the delivery of insulin to the liver was high, as in the obese-NL and obese-NAFLD groups, because of a saturable hepatic
insulin transport system. Most of the insulin that passes through the liver and enters the systemic circulation is recycled back to the liver, and a progressively increasing amount of insulin was removed by extrahepatic tissues (primarily the kidneys and skeletal muscle) in subjects in the lean-NL, obese-NL,
and obese-NAFLD groups. A small portion of insulin that entered the systemic circulation (posthepatic insulin) was not removed by 180 minutes after
glucose ingestion and was responsible for the increase in plasma insulin concentration above baseline at the 180-minute time point.

OGTT and the HECP. Third, our study is a cross-sectional analysis
of weight-stable participants, so we cannot exclude the possibility
that changes in insulin kinetics occur over time or in response to
changes in diet or body weight.
In summary, the large increase in plasma insulin concentrations in response to an oral glucose challenge that is commonly
observed in individuals with obesity and further exacerbated in
individuals with obesity who have NAFLD and greater insulin
resistance was driven by increased insulin secretion, without
an intrinsic defect in hepatic or extrahepatic insulin extraction.
Therefore, the progressive decrease in whole-body insulin clearance rates (volume of plasma cleared of insulin per unit of time)
from lean-NL to obese-NL to obese-NAFLD was probably a consequence, rather than a cause, of hyperinsulinemia. The rate of insulin extraction by the liver, but not by extrahepatic tissues, became
saturable when the postprandial delivery of insulin to the liver was
high. In individuals with severe insulin resistance, the increased
delivery of insulin to the liver and extrahepatic tissues was unable
to compensate for the decrease in insulin sensitivity, resulting in
impaired glucose homeostasis.

Methods

Subjects. A total of 60 men and women participated in this study
(see Supplemental Figure 3 for the flow chart of study subjects).
Subjects were recruited using the Volunteers for Health database
at Washington University School of Medicine and by local postings
between April 2016 and November 2018. All procedures for this
study were conducted in the Clinical Translational Research Unit
(CTRU) and Center for Clinical Imaging Research (CCIR) at Washington University School of Medicine. Potential subjects completed
an initial evaluation that included a medical history and physical
examination, standard blood tests, a 3-hour OGTT and an assessment of body composition including IHTG content. Subjects were
enrolled if they met the criteria for inclusion in 1 of 3 groups: (a)
lean-NL individuals, defined as having a BMI of 18.5 to 24.9 kg/m2
and normal fasting plasma glucose (<100 mg/dL), oral glucose tolerance (2-hour glucose <140 mg/dL), and IHTG content (≤5%) (n =
14; age: 36 ± 2 yr; sex: 7 men and 7 women; race: 9 Whites, 1 African
American, and 4 Asians); (b) obese-NL individuals, defined as having a BMI of 30.0 to 49.9 kg/m2 and normal fasting plasma glucose,
oral glucose tolerance, and IHTG content (n = 24; age: 39 ± 2 yr;
jci.org   Volume 130   Number 6   June 2020
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sex: 3 men, 21 women; race: 13 Whites and 11 African Americans);
and (c) obese-NAFLD individuals, defined as having a BMI of 30.0
to 49.9 kg/m2, impaired fasting glucose or oral glucose tolerance,
and high IHTG content (≥10%) (n = 22; age: 42 ± 2 yr; sex: 6 men
and 16 women; race: 17 Whites, 4 African Americans, and 1 Pacific
Islander). None of the subjects had evidence of diabetes, serious illnesses other than NAFLD, was taking medications that could interfere with insulin action or secretion, consumed excessive amounts
of alcohol (>14 drinks/week for women and >21 drinks/week for
men), or smoked tobacco products.
Body composition analyses. Total body fat and fat-free mass (FFM)
were determined by using dual-energy x-ray absorptiometry (Lunar
iDXA, GE Healthcare), and IHTG content was determined by MRI
(3.0-T superconducting magnet; Siemens) (5).
OGTT. Subjects were admitted to the CTRU at Washington University School of Medicine at 0700 hours after subjects fasted for
approximately 11 hours overnight at home. An intravenous catheter
was inserted into an antecubital or hand vein for serial blood sampling. Plasma glucose, insulin, and C-peptide concentrations were
determined 15, 10, and 5 minutes before and 10, 20, 30, 60, 90, 120,
150, and 180 minutes after consuming a 75-g glucose beverage. The
average of the 3 baseline samples (i.e., –15, –10, and –5 minutes before
consuming the 75-g glucose beverage) was used as the t = 0 glucose,
insulin, and plasma C-peptide concentrations.
HECP. Subjects were admitted to the CTRU at 1800 hours for
approximately 48 hours. Participants were given standard meals containing one-third of their estimated energy requirements (40) upon
admission (day 0) and at 0700 hours, 1300 hours, and 1900 hours on
day 1. The HECP was performed on day 2, after subjects fasted overnight. At 0700 hours, a primed (8.0 μmol/kg), continuous (0.08 μmol/
kg/min) infusion of [U-13C]glucose (Cambridge Isotope Laboratories
Inc.) was started. After the infusion of glucose tracer for 3.5 hours (basal period), insulin was infused at a rate of 50 mU/m2/min (initiated
with a 2-step priming dose of 200 mU/m2/min for 5 minutes followed
by 100 mU/m2/min for 5 minutes), and euglycemia (~100 mg/dL) was
maintained by variable-rate infusion of a 20% dextrose solution that
was enriched to approximately 1% with [U-13C]glucose. The infusion
of [U-13C]glucose was stopped during insulin infusion because of the
expected decrease in hepatic glucose production. Blood samples were
obtained before beginning the glucose tracer infusion and every 6 to
7 minutes during the last 20 minutes of the basal and insulin infusion
stages to determine glucose, C-peptide, and insulin concentrations
and glucose kinetics.
Sample analyses and calculations. Blood samples were collected in
chilled tubes containing EDTA or heparin and placed in ice. Plasma
was separated by centrifugation within 30 minutes of collection and
then stored at –80°C until final analyses. The plasma glucose concentration was determined using the glucose oxidase method (YSI Inc.),
and plasma insulin and C-peptide concentrations were determined
using electrochemiluminescence assays (Elecsys 2010, Roche Diagnostics). The plasma glucose tracer-to-tracee ratio was determined by
gas-chromatography/mass-spectrometry as described previously (41).
Plasma glucose, insulin, and C-peptide concentration AUCs
during the OGTT were calculated using the trapezoidal method (42).
Hepatic insulin sensitivity was calculated as the reciprocal of the product of the basal endogenous glucose production rate (in μmol/kg FFM/
min) and the basal plasma insulin concentration (in μU/mL) (1). Total
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glucose Rd during insulin infusion was assumed to be equal to the sum
of the endogenous glucose rate of appearance into the bloodstream
and the rate of infused glucose during the last 20 minutes of the HECP
(1). An index of muscle insulin sensitivity was calculated as the glucose
Rd expressed per kilogram of FFM divided by the plasma insulin concentration (glucose Rd/I) during the final 20 minutes of the HECP.
Insulin secretion rates were calculated using C-peptide deconvolution
(43). Insulin secretion in relationship to insulin sensitivity was used to
provide an index of β cell function and calculated as the product of the
incremental AUC in the ISR above time 0 from 0 to 180 minutes of the
OGTT, and insulin sensitivity was assessed during the HECP (ΔISR0-180
× glucose Rd/I).
The whole-body insulin clearance rate (i.e., volume of plasma
cleared of insulin per minute) was calculated using a 1-compartment
model for plasma insulin: (AUC ISR/AUC I) – V × (I180 – I0)/AUC I,
where V is the distribution volume for insulin estimated as 141 mL/
kg (19), and I0 and I180 are the plasma insulin concentrations at time 0
(baseline) and 180 minutes, respectively, during the OGTT. A recently
developed mathematical modeling approach that involves the use of
plasma insulin concentration and ISR data from both the OGTT and
HECP (15, 19) was used to provide a comprehensive assessment of
the kinetics of hepatic and extrahepatic insulin removal from plasma
during the OGTT. In this model, hepatic insulin clearance for each
subject was modeled using either a linear or saturable model, and the
model that provided the better fit was used for that subject. In addition, extrahepatic insulin clearance was assumed to be linear; this
assumption was confirmed by testing a saturable model for extrahepatic insulin clearance, and finding a linear model provided the best
fit of the data for all subjects. The following measurements of insulin kinetics were determined: (a) fractional hepatic insulin extraction
(i.e., the fraction of insulin delivered to the liver that is removed by
the liver); (b) total hepatic insulin extraction rate (i.e., molar amount
of insulin removed from plasma by the liver per minute); (c) rate of
insulin recycled from the systemic circulation back to the liver (i.e.,
insulin that passes through the liver into the systemic circulation that
is not removed by extrahepatic tissues and is recycled back to the liver); (d) rate of extrahepatic insulin extraction (i.e., molar amount of
insulin removed from plasma by extrahepatic tissues per unit of time);
and (e) whole-body insulin extraction rate (i.e., sum of the hepatic and
extrahepatic insulin extraction rates).
Statistics. A 1-way ANOVA was used to compare characteristics
of subjects in the lean-NL, obese-NL, and obese-NAFLD groups.
Between-group differences in the insulin secretion rate, clearance
rate, total extraction rate, and fractional extraction were assessed
using ANCOVA with race and sex as covariates. Where appropriate,
post hoc analyses were used to locate significant mean differences.
Modeled and measured plasma insulin concentration profiles were
compared using the normalized root mean square error, as previously
described (15, 19). The significance of the relationships among outcome measures were evaluated using either linear or nonlinear regression. Relationships that involved IHTG content were analyzed separately for subjects with normal IHTG content (lean-NL and obese-NL
groups) and high IHTG content (obese-NAFLD group), because there
was no continuum in IHTG content according to the study’s design.
The relationship between the whole-body insulin extraction rate and
the plasma insulin concentration AUC during the OGTT was assessed
using Michaelis-Menten kinetics to determine whether the rate of
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insulin extraction could be explained by saturable, receptor-mediated
insulin uptake. Statistical significance was defined as a P value under
0.05. Statistical analyses were performed using SPSS, version 25
(IBM). Data are reported as the mean ± SEM. On the basis of the interindividual variability in fractional hepatic insulin extraction we previously reported (15), we estimated that 15 subjects in each group would
be needed to detect between-group differences in fractional hepatic
insulin extraction rates of 20% using a 2-sided test with a β value of
0.9 and an α value of 0.05. These computations were performed using
G*Power, version 3.1.9.2 (44).
Study approval. All subjects provided written informed consent
before participating in this study, which was approved by the Human
Research Protection Office of Washington University School of Medicine.
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